STELLAR-305: Zanzalintinib in Combination with Pembrolizumab as First Line Therapy for Recurrent or Metastatic Disease
Condition: Head and Neck Squamous Cell Carcinoma
Sponsor: Exelixis
Full Title
Protocol XL092-305: A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in the First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Study Treatment
Zanzalintinib, an oral RTK inhibitor, in combination with pembolizumab vs pembrolizumab alone
Eligibility/Info
- Recurrent or metastatic head and neck squamous cell carcinoma (oropharynx, oral cavity, hypopharynx, larynx)
- PD-L1 CPS ≥ 1
- No history of treatment for recurrent or metastatic head and neck squamous cell carcinoma
- No progressive disease within 6 months of local therapy (if given)
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
